Theravance Inc  

(Public, NASDAQ:THRX)   Watch this stock  
Find more results for THRX
+0.05 (0.55%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.02 - 9.15
52 week 6.36 - 21.16
Open 9.08
Vol / Avg. 245,426.00/902,620.00
Mkt cap 1.06B
P/E     -
Div/yield 0.25/11.01
EPS -0.34
Shares 117.43M
Beta 1.76
Inst. own 84%
Feb 16, 2016
Q4 2015 Theravance Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 18, 2015
Theravance Inc at Stifel Healthcare Conference
Nov 11, 2015
Theravance Inc at Credit Suisse Healthcare Conference
Oct 28, 2015
Q3 2015 Theravance Inc Earnings Call - Webcast
Oct 28, 2015
Q3 2015 Theravance Inc Earnings Release
Sep 17, 2015
Theravance Inc at Morgan Stanley Healthcare Conference
Sep 9, 2015
Theravance Inc at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -33.80% -871.93%
Operating margin 62.19% -402.34%
EBITD margin - -257.96%
Return on average assets -4.09% -12.23%
Return on average equity - -194.08%
Employees 13 -
CDP Score - -


951 Gateway Blvd
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Theravance, Inc. is a royalty management company. The Company is focused on managing its respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI), with the intention of providing capital returns to stockholders. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI), a long-acting beta2 agonist (LABA) and fluticasone furoate (FF), an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA) for the treatment of chronic obstructive pulmonary diseases (COPD). BREO ELLIPTA and ANORO ELLIPTA are not indicated for the relief of acute bronchospasm or the treatment of asthma in the United States and Canada.

Officers and directors

William H. Waltrip Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
George B. Abercrombie Senior Vice President - Corporate Partnerships, Commercial
Age: 60
Bio & Compensation  - Reuters
Michael E. Faerm Senior Vice President and Chief Business Officer
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President - Corporate Partnerships, Clinical and Medical Affairs
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Catherine J. Friedman Independent Director
Age: 54
Bio & Compensation  - Reuters
Terrence C. Kearney Independent Director
Age: 60
Bio & Compensation  - Reuters
Paul Pepe Independent Director
Age: 56
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 62
Bio & Compensation  - Reuters